Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
gevokizumab × Clear all
NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Novartis

Phase 1 Completed
167 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT05178576 2022-11-04

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

NSABP Foundation Inc

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡